Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia

Leukemia Research

Volumn 25, Issue 6, 2001, Pages 435-440

  Waselenko, Jamie K ^a,b   Grever, Michael R ^c   Shinn, Charlotte A ^d   Flinn, Ian W ^d   Byrd, John C ^b,d  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; Gemcitabine

Indexed keywords

ANTILEUKEMIC AGENT; FLUDARABINE; GEMCITABINE; LIPOCORTIN 5; PROPIDIUM IODIDE; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TETRAZOLIUM;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL ISOLATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING; WESTERN HEMISPHERE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; DEOXYCYTIDINE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035030512     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00106-5     Document Type: Article

References (19)

1. Cancer statistics
2. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB SWOG, CTG/NCI-C and ECOG Inter-Group Study
3. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia
4. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine)
5. Induction of resistance to 2′-2′-difluorodeoxycytidine in the human ovarian cancer cell line A2780
6. Quantitative immunoassay of human deoxycytidine kinase in malignant cells
7. Phase II study with gemcitabine in pretreated patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL): results of a multicenter study
8. Gemcitabine is active in relapsed Hodgkin's disease
9. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment
10. Clinical staging of chronic lymphocytic leukemia
11. Monoclonal antibody analysis of p53 expression on normal and transformed cells
12. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study
13. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy
14. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumor cells and tissues
15. Gemcitabine is a pancytotoxic drug for various multiple myeloma cell lines, whereas taxol cytotoxicity is dependent on expression of bcl-2
16. Pharmacologicaly directed design of the dose rate and schedule of 2-2-diflurodeoxycitidine (gemcitabine) administration in leukemia
17. Saturation of 2′,2′-diflurodeoxycitidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
18. Gemcitabine: current status of phase I and II trials
19. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5′-NT and Bax/Bcl-2